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Abstract
The COVID-19 pandemic has been labeled one of the most lethal pandemics in human history. As a result, there has
been a high level of urgency throughout the world to establish successful vaccinations to subdue the effects of the virus
and return to a level of normalcy. This study aims to investigate the different COVID-19 vaccines available both in the
United States and across the globe. Through exploration of how the vaccines were developed, how they elicit immunity,
their efﬁcacy, and their safety proﬁles, this review has the goal of increasing the amount of knowledge regarding the
vaccines available to combat SARS-CoV-2, while also providing an epidemiological and biostatistical approach to
interpreting acquired data available on the vaccines.
Keywords: COVID-19, Vaccine, Immunity, SARS-COV2, Efﬁcacy

1. Introduction and background

T

he severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus that was ﬁrst
identiﬁed in the city of Wuhan, China in December
of 2019, has led to an outbreak of illness that has
been declared a public health emergency by the
World Health Organization (WHO), an agency of
the United Nations responsible for international
public health.1 Widespread vaccination against
SARS-CoV-2 has been considered to be the most
propitious approach to curb the pandemic.2 Therefore, unparalleled measures have been taken to
manufacture and distribute a sufﬁcient number of
vaccines to immunize an adequate number of individuals to protect communities from the
continued perils of morbidity and mortality from
SARS-CoV-2. Historically, vaccine development has
been known to take years to decades before a ﬁnal
product can become available for the general public.
For example, the polio vaccine took 40 years to reach
the public platform.3,4 The development and
approval of a vaccine requires advancements
through a preclinical evaluation and three discrete
clinical phases. The preclinical evaluation typically

consists of testing on animal models in order to
assess for the level of antigen recognition, toxicology, and protective effects of the proposed vaccine. Phase I trials are designed to test vaccine safety
and are centered around ﬁnding a balanced dose
that the human body can tolerate without having
serious side effects.5 Phase II trials expand the safety
proﬁle and immune response assessment in a larger
number of participants while also taking into
consideration the effect of different variables such as
age, gender, ethnicity, and the presence of other
comorbid disease. Phase III trials are designed to
determine efﬁcacy through utilization of blinded
randomized controlled trials.5 These phases are
conducted systematically and in a measurable
stride. Therefore, before engaging resources in a
subsequent phase, it is important to ensure that the
data from previous phases is convincing enough to
warrant further development.5 However, during
this public health emergency, vaccine development
for SARS-CoV-2 has been expedited, and as a result,
multiple vaccines have been made available
worldwide in record time. Although several phases
have progressed simultaneously, safety criteria have
remained stringent. In the United States, the Food
and Drug Administration (FDA) has approved the
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progression of phases based on data generated in
the prior steps and has also allocated massive
ﬁnancial resources into vaccine development.
Within months, several vaccine candidates have
entered the clinical development pipeline.6 There
are three types of COVID 19 vaccines available: a
genetic vaccine, a viral vector vaccine, and an inactivated/attenuated vaccine. The ﬁrst two vaccines
that have been made available in the USA have
been created by Pﬁzer-BioNTech and Moderna, and
are both genetic, or messenger RNA (mRNA) vaccines. As time progressed, vaccines using adenovirus vectors began to become available. The viral
vector vaccines available include one developed by
Janssen-Johnson & Johnson in the USA, and others
developed by Astra-Zeneca, Sputnik-V, and CanSino outside the USA. Another type of vaccine
developed are inactivated whole-virus SARS-CoV-2
vaccines made by Bharat Biotech and Sinovac,
which are only available outside the United States.7

2. Review of literature
2.1. Materials and methods
A non-systematic search of the literature in the
PubMed and MEDLINE database using the term
“COVID-19 vaccine” was undertaken until May
12th, 2021. The database identiﬁed 7601 results out
of which, 34 studies including randomized
controlled trials (RCTs), non-RCTs, and quasi-RCTs
were reviewed to assess the indications, administration, immunogenicity, efﬁcacy, safety and side
effects proﬁle. The studies were selected with the
thought in mind to have the most recent and up to
date data that held statistical signiﬁcance.
2.2. Mechanisms of action
After the SARS-CoV-2 genetic sequence was
determined in January 2020, a lipid-nanoparticle
(LNP) encapsulated mRNA vaccine expressing the
prefusion-stabilized spike glycoprotein was developed by two companies, Pﬁzer-BioNTech and Moderna. The mechanism of action of mRNA vaccines is
through targeted delivery of mRNA, which is then
translated using the hosts cellular machinery to
produce a folded, functional protein against which
the adaptive immune system becomes targeted.8 The
use of mRNA as the primary component in order to
stimulate immunity against the virus has been
shown to have numerous advantages including a
higher safety proﬁle, increased efﬁcacy, as well as
low expenditure.8,9 The Pﬁzer-BioNTech SARS-CoV2 vaccine, referred to as BNT162b1, contains mRNA

that encodes a speciﬁc portion of the spike protein,
the receptor-binding domain (RBD), which plays an
important role in attaching to and infecting host cells.
In order to establish higher degrees of immunogenicity, the vaccine also contains the addition of a T4
ﬁbritin-derived foldon trimerization domain to the
RBD antigen.10 Furthermore, to help facilitate entry
of the mRNA into cells and to prevent degradation
by extracellular RNases the mRNA in this vaccine is
coated in cationic lipid nanoparticles.8,11 Moderna's
SARS-CoV-2 vaccine, known as mRNA-1273, contains mRNA that encodes for the entire full length
spike protein of SARS-CoV-2 instead of only the
RBD, however, it is also composed of mRNA coated
in lipid nanoparticles.11,12 Ad26.COV2.S, a vaccine
developed by Janssen-Johnson & Johnson, and
AZD1222, a vaccine developed by Oxford-AstraZeneca, both use a viral vector as their primary
component. Viral vector vaccines use a recombinant
attenuated virus that is designed to encode a particular antigen sequence and is introduced into host
cells via a process known as transduction. Thereby,
there is endogenous production of the antigen of
interest, which in turn stimulates the humoral and
cellular immune systems. Viral vector vaccines have
the ability to be either replicating or nonreplicating.
Replicating vectors having the power to produce a
more ampliﬁed and immunogenic response, but also
risk having the capability of reverting to virulence.
Instead, non-replicating viral vectors have the
inability to produce virulence, however, increased
dosing is needed to confer an efﬁcient level of immunity.13,14 The Ad26.COV2.S vaccine uses a human
adenovirus type 26 vector that is nonreplicating and
that encodes a version of the spike “S” protein of
SARS-CoV-2, stabilized by two proline mutations.
The vaccine created by Oxford-AstraZeneca, named
AZD1222, is similar to Ad26.COV2.S in that it is a
viral vector vaccine, however, it uses a strain of
adenovirus that is only found in chimpanzees called
ChAdOX1.14,15 BBV152, a vaccine developed by
Bharat Biotech and available outside the United
States, is created differently from most available
vaccines as it contains an entire virion inactivated
SARS-CoV-2, which is produced in Vero cells.16 Vero
cells are derived from the kidney of an African green
monkey, the grivet, and are commonly used in
mammalian research pertaining to molecular and
cellular biology. The growth and culture properties
of Vero cells, particularly its continuous lineage,
allow it to replicate through numerous cycles of division. Vero cells have been licensed in the United
States for the production of both live and inactivated
viral vaccines, including the inactivated poliovirus
vaccine.17,18

2.3. Efﬁcacy
In a large phase III trial of over 36,000 participants
aged 16 years or older, an analysis of 170 conﬁrmed
COVID-19 cases (8 in the vaccine group versus 162
in the placebo group), demonstrated that the PﬁzerBioNTech COVID vaccine had 95 percent efﬁcacy
(95% CI 90.3e97.6) in preventing symptomatic
COVID-19 on and even after seven days following
the second dose with a median follow up of 2
months.19,20 These results could be interpreted into
saying that in a population of those who received
two doses of the Pﬁzer-BioNTech COVID vaccine,
95% of the time, 90.3 to 97.6 of that population will
not present with symptomatic disease. Additionally,
nine out of the ten severe cases that occurred during
the study were in the placebo group. In a multivariate analysis, which is historically based on an
analysis of more than one variable, results showed
that in adults 65 years with either established
medical comorbidities or obesity, the vaccine
demonstrated an efﬁcacy of 91.7 percent (95% CI
44.2e99.8). The vaccine efﬁcacy was 100% (95% CI
75.3e100) among 1983 participants aged 12e15 years
without evidence of prior infection.21 Hence, the
vaccine is approved by the US FDA for the emergency use authorization (EUA) to include adolescents 12 through 15 years of age.22 The trial ﬁndings
corroborated the observational data from various
countries.23e26 In Israel, a study using national surveillance data from more than 6.5 million individuals, out of which 72 percent had received
BNT162b2, reports estimated vaccine effectiveness
seven days or more following the second dose was
92 percent for COVID-19 infection, 97 percent for
symptomatic COVID-19, 97 percent for COVID-19related hospitalization, and 97 percent for COVID19-related death.23
The Moderna mRNA-1273 vaccine had a 94.1
percent vaccine efﬁcacy (95% CI 89.3e96.8) in preventing symptomatic COVID-19 at or after 14 days
following the second dose in a large placebocontrolled phase III clinical trial.27 This trial had
nearly 30,000 study participants aged 18 years and
older, that ensued in 196 conﬁrmed COVID-19 cases
(11 in the vaccine group and 185 in the placebo
group) with a median follow-up of two months after
vaccination. The vaccine efﬁcacy was 86.4 percent
(95% CI 61.4e95.5) among adults 65 years of age.
All thirty severe cases happened in the placebo
group. Observational data evaluating vaccine effectiveness also supported the trial ﬁndings. The estimated vaccine effectiveness for preventing COVID19 hospitalization was 94 percent, which was shown
in a study of 489 individuals, 65 years, only one
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individual with conﬁrmed COVID-19 by SARSCoV-2 testing (0.5 percent) was hospitalized that
had received the recommended two doses of an
mRNA vaccine, although conﬁdence intervals were
wide because of the small sample size.28
The Janssen-Johnson & Johnson (Ad26.COV2.S)
vaccine in a phase III clinical trial, given as a
single dose, had 66.9 percent efﬁcacy (95% CI
59.0e73.4) in preventing COVID-19 infection at or
after 14 days following vaccination.14 This trial was
done in 40,000 study participants aged 18 years
and older with a median follow-up of two months
after vaccination, with 464 conﬁrmed moderate to
critical COVID-19 cases (116 in the vaccine group
and 348 in the placebo group). At 14- and 28-days
post-vaccination, the vaccine efﬁcacy against severe/critical disease was 78 and 85 percent
respectively.14
The Oxford-AstraZeneca (AZD1222) vaccine, in a
report from a multinational phase III randomized
trial comprising over 11,000 patients showed, the
vaccine had 70.4 percent efﬁcacy (95% CI 54.8e80.6)
in preventing symptomatic COVID-19 at or after 14
days following the second dose.29 On analysis, there
were 131 conﬁrmed COVID-19 cases (30 in the
vaccine group and 101 in the control group). All of
the ten hospitalized COVID patients, including two
severe COVID-19 patients were in the control
group. In a subsequent analysis of this trial, vaccine
efﬁcacy for revealed that receipt of the second dose
at 12 weeks or later was associated with higher
vaccine efﬁcacy than receipt at <6 weeks (81 versus
55 percent).30 These ﬁndings contributed support to
extending the time interval for the second dose to 12
weeks. In Scotland, a nationwide that included over
600,000 individuals who received at least one dose of
vaccine was associated with an 88 percent reduction
in hospitalization for COVID-19 in the fourth week
after vaccination.24 Covaxin, also known as BBV152,
which was developed in India by Bharat Biotech,
has not had published efﬁcacy trial, however a press
release stated that among 25,800 participants reported an efﬁcacy rate of 81 percent against symptomatic COVID-19 after an interim analysis of 43
cases (36 with placebo and 7 with vaccine).31 The
rest of the trial results have not yet been made
public.
The above trials use 95% conﬁdence interval
which are a range of values that you can be 95%
conﬁdent contains the true mean of the population.
The studies also use median numbers rather than
mean to return the central tendency for skewed
number distributions otherwise the value of the
mean would be dominated by the outliers rather
than the typical values.
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2.4. Safety and side effects
Local and systemic adverse effects with PﬁzerBioNTech COVID vaccine are relatively common,
particularly after the second dose. Most of the
adverse effects are of mild or moderate severity (ie,
do not prevent daily activities) and are limited to the
ﬁrst two days after vaccination.19,32,33 Among 1.6
million vaccine recipients in the United States, a
local injection site reaction comprised of pain,
redness and swelling was reported in approximately
65 percent after each dose. Other mild side effects
including fatigue, headache, and myalgias were reported in 29 and 48, 25 and 40, and 17 and 37 percent
after the ﬁrst dose and the second, respectively.19
These reactions were also commonly reported
among adolescents aged 12e15 years and less
frequently among recipients 65 years or older but
are still relatively common. In about 5 events per
one million doses, anaphylaxis following vaccination has been reported.34 Bell's palsy has also been
noted in the phase III trial (four in vaccine and zero
in placebo recipients),19 however, the rate did not
exceed those found in the general population. No
other major vaccine-associated adverse events were

identiﬁed.33 Similarly, in the Moderna mRNA-1273
vaccine, local and systemic adverse effects are
relatively common, particularly after the second
dose. Most of the adverse effects are of mild or
moderate severity (ie, do not prevent daily activities)
and are limited to the ﬁrst two days after vaccination.32,33,35 In a survey amongst 2 million vaccine
recipients in the United States, an injection site reaction that comprised of pain, redness and swelling
was reported in approximately 74 and 82 percent
after ﬁrst and second dose respectively. Other mild
side effects including fatigue, headache, and myalgias were reported in 33 and 60, 27 and 53, and 21
and 51 percent after the ﬁrst dose and the second,
respectively.19 Among recipients aged 65 years or
older, the local and systemic reactions occurred less
frequently but were still relatively common.
Anaphylaxis has been reported in about 2.8 events
per one million doses.34,36 Following the ﬁrst
7,581,429 doses of mRNA-1273 administered in the
United States, 21 cases of anaphylaxis were reported
to the CDC, with 86 percent occurred among individuals with pre-existing allergies, and 90 percent
occurred within 30 min. Bell's palsy has also been
noted in the clinical trial (three in vaccine and zero

Table 1. Showing COVID- 19 Vaccine comparisons.
Pﬁzer (BNT162b1)

Moderna (mRNA1273)

Janssen-Johnson&Johnson
(Ad26.COV2.S)

Oxford-AstraZeneca (AZD1222)

Bharat
(BBV152)

Number of
Doses

Two doses, 0.3 mL
each, 21 days
apart.19

Two doses, 0.5 mL
each, 28 days
apart.35

One dose, 0.5 mL14

Two doses 29 days
apart.31

Age considerations

Approved for ages
12 and up.19,22
36,00019,20

Approved for ages
18 and up.35
30,00027

Approved for ages
18 and up.14
40,00014

Two doses 4e12
weeks apart. The
World Health Organization (WHO)
recommends that
the two doses be
given 8e12 weeks
apart29
Approved for ages
18 and up29
11,00029

mRNA19,20

mRNA26

Viral Vector14

95% effective in
preventing symptomatic COVID-19
97% effective in
preventing severe
disease 97% effective in preventing
death and
hospitalization19,20
Injection site pain,
fatigue, fever headache, muscle pain,
joint pain, anaphylactic reaction.19

94.1% effective in
preventing symptomatic COVID-19
100% effective in
preventing severe
disease 94% effective in preventing
death and
hospitalization27
Injection site pain,
fatigue, fever,
headache, muscle
pain, joint pain,
fever, anaphylactic
reaction.32,33,35

66.9% effective in
preventing symptomatic COVID-19
78 and 85% effective in preventing
severe disease at
14- and 28-days
post vaccination.14

Number of
subjects tested
Vaccine type
Efﬁcacy

Side effects

Injection site reactions, headache,
fatigue, myalgia,
nausea, fever,
thromboembolic
events.37

70.4 percent efﬁcacy in preventing
symptomatic
COVID-19 Associated with an 88%
reduction in hospitalization in the 4th
week after
vaccination.29
Fever, headache
and thromboembolic events.37

Biotech

Approved for ages
18 and up31
25,80031
Inactivated whole
virion
81% efﬁcacy rate in
preventing symptomatic COVID-1931

Injection site pain,
fever, fatigue, malaise, headaches.31

in placebo recipients).34 However, the rate did not
exceed those found in the general population. No
other major vaccine-associated adverse events were
identiﬁed.33
In the Janssen-Johnson & Johnson (Ad26.COV2.S)
vaccine, local and systemic adverse effects are also
reported to be relatively common. Most effects are
of mild or moderate severity (ie, do not prevent
undertaking daily activities) and most commonly
occur the ﬁrst day after vaccination.35 Among over
330,000 vaccine recipients in the United States, 76
percent reported at least one systemic reaction and
61 percent at least one injection site reaction in the
ﬁrst week. Fatigue, pain, and headache were the
most common systemic reactions. Serious adverse
event rates in the vaccine and placebo group were
similar.29 In vaccinated patients compared with
placebo patients, there were more cases of thromboembolic events (11 versus 3) and seizures (4
versus 1), but these events were not signiﬁcant to
determine whether there is a causal association with
vaccination.29,37
In the Oxford-AstraZeneca (AZD1222) vaccine,
the earlier-phase trial data reveals mild to moderate
side effects like fatigue, headache, and fever in up to
8 percent of recipients.38 There were two reported
cases of transverse myelitis. The vaccine has also
been associated with an extremely small risk of
thrombotic events associated with thrombocytopenia. No clear-cut data regarding vaccine adverse
effects is yet available for Covaxin by Bharat
Biotech.
Table 1 is depicting the comparisons between
BNT162b1, mRNA-1273, Ad26.COV2.S, AZD1222
and BBV152 COVID-19 vaccines.

3. Conclusion
While the ﬁve vaccines mentioned may share
their fair amount of similarities and differences,
there is no uncertainty in stating that the data from
this study shows that they all are efﬁcacious in
preventing COVID-19 and its complications.
Although going against historical precedent in regard to how rapidly they were produced, COVID19 vaccine development was nonetheless rooted in
a strong understanding of vaccine technology and
immunogenicity, with safety protocols still kept to a
high level of importance. With the numbers of individuals who are vaccinated against COVID-19
climbing every single day, there is hope that a return to normalcy will arrive sooner rather than
later.
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